We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

97 hedge funds and large institutions have $241M invested in Cue Biopharma in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

82% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 22

5% more funds holding

Funds holding: 92 → 97 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.08% less ownership

Funds ownership: 2.21% → 2.13% (-0.08%)

17% less capital invested

Capital invested by funds: $291M → $241M (-$49.8M)

87% less call options, than puts

Call options by funds: $359K | Put options by funds: $2.72M

Holders
97
Holders Change
+5
Holders Change %
+5.43%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
13
Increased
40
Reduced
22
Closed
7
Calls
$359K
Puts
$2.72M
Net Calls
-$2.36M
Net Calls Change
-$2.55M

Top Buyers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
+$6.36M
2
Morgan Stanley
Morgan Stanley
New York
+$4.04M
3
PM
Prosight Management
Texas
+$2.62M
4
Millennium Management
Millennium Management
New York
+$2.42M
5
Goldman Sachs
Goldman Sachs
New York
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$18.9M
2
WP
Woodline Partners
California
-$5.39M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.53M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$1.29M
5
BL
Bleichroeder LP
New York
-$999K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCG
26
Rock Creek Group
District of Columbia
$1.25M +$267K +667 +25%
CC
27
Carlson Capital
Texas
$1.06M +$1.13M +2,833 New
BL
28
Bleichroeder LP
New York
$938K -$999K -2,500 -50%
SPC
29
Sigma Planning Corp
Michigan
$895K +$157K +392 +20%
Renaissance Technologies
30
Renaissance Technologies
New York
$854K -$735K -1,840 -45%
Stifel Financial
31
Stifel Financial
Missouri
$824K – – –
GCP
32
GSA Capital Partners
United Kingdom
$804K +$260K +650 +44%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$797K -$43.2K -108 -5%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$786K -$38.8K -97 -4%
AC
35
Apogem Capital
New York
$701K +$746K +1,868 New
CS
36
Credit Suisse
Switzerland
$694K -$42K -105 -5%
Swiss National Bank
37
Swiss National Bank
Switzerland
$668K +$24K +60 +3%
Wells Fargo
38
Wells Fargo
California
$658K -$2K -5 -0.3%
Russell Investments Group
39
Russell Investments Group
United Kingdom
$636K +$237K +592 +54%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$554K +$9.99K +25 +2%
Marshall Wace
41
Marshall Wace
United Kingdom
$473K +$504K +1,262 New
Deutsche Bank
42
Deutsche Bank
Germany
$471K +$179K +447 +55%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$437K +$9.99K +25 +2%
AllianceBernstein
44
AllianceBernstein
Tennessee
$399K – – –
AQR Capital Management
45
AQR Capital Management
Connecticut
$391K -$74.3K -186 -15%
Bank of America
46
Bank of America
North Carolina
$356K -$55.9K -140 -13%
Citadel Advisors
47
Citadel Advisors
Florida
$348K -$2.53M -6,320 -87%
CAM
48
ClariVest Asset Management
California
$339K +$112K +280 +45%
Squarepoint
49
Squarepoint
New York
$328K +$83.5K +209 +31%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$318K – – –
1
2
3 4 5

CUE Hedge Fund Activity: Q4 2020 in Review

97 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2020, worth a combined $241M — down 17% from $291M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CUE positions and 7 closed out — a net gain of 6 holders — while 40 added to existing stakes and 22 trimmed.

The largest buyer was Corriente Advisors, adding an estimated $6.36M. The largest seller was Avoro Capital Advisors, cutting an estimated $18.9M.

  • 97 institutional investors held Cue Biopharma (CUE) as of Q4 2020, up from 92 in Q3 2020.
  • Funds reported $241M of Cue Biopharma stock for Q4 2020, down 17% quarter-over-quarter.
  • 13 funds opened new Cue Biopharma positions in Q4 2020 and 7 closed out, a net change of +6 holders.
  • The largest Cue Biopharma buyer in Q4 2020 was Corriente Advisors, an estimated $6.36M added.
  • The largest Cue Biopharma seller in Q4 2020 was Avoro Capital Advisors, an estimated $18.9M sold.

Based on aggregated 13F filings for Q4 2020.